Company intelligence / Profile preview

MaaT Pharma

Ownership: Public · MAAT
Employees: ~64
Development stage: Phase 3

Overview

MaaT013 achieved positive efficacy and safety results in pivotal Phase 3 trial for GI-aGvHD with plans to submit to EMA mid–2025. MaaT033 showed good safety/tolerability and engraftment in both hematological malignancy patients and ALS patients. First-in-human study of next-gen synthetic product MaaT034 planned for late–2025.

Therapeutic areas: HematologyImmunologyOncologyNeurology
Modalities: Microbiome Ecosystem Therapies (MET)Live Biotherapeutic Products (LBP)Cell therapy approaches for microbiome modulation
Industry: Biotech

Drug pipeline

10 assets

MaaT-033

9 more assets in the full pipeline.

Request access →

Partnerships

Academic hospitals across Europe running clinical trialsCollaborations with leading academic institutions via investigator-sponsored studiesNo major pharma partnerships publicly disclosed.

Beyond the preview

Go deeper on MaaT Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MaaT Pharma.

Explore the full profile